07-11-2024 |
PM |
|
ESPR |
Esperion Therapeutics, Inc. |
416.00 |
-0.15 |
-0.14 |
-0.37 |
Esperion Therapeutics gives mixed Q3 results [11/7/2024 6:03 AM] |
2.10 |
-0.10 (-4.75%) |
1.98 |
-0.23 (-10.41%) |
0.87 - 3.40 |
8,880,708 |
3,340,000 |
994,785 |
|
|
12-08-2024 |
PM |
|
ESPR |
Esperion Therapeutics, Inc. |
384.60 |
-0.05 |
-0.15 |
-0.46 |
Esperion Therapeutics GAAP EPS of -$0.33 misses by $0.16, revenue of $73.83M beats by $24.77M [8/12/2024 6:02 AM] |
1.82 |
-0.20 (-9.65%) |
1.88 |
-0.14 (-6.93%) |
0.70 - 3.40 |
7,473,450 |
4,430,000 |
1,273,258 |
|
|
07-05-2024 |
PM |
|
ESPR |
Esperion Therapeutics |
390.00 |
0.34 |
-0.17 |
0.00 |
Esperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook [5/7/2024 6:04 AM] |
2.40 |
0.28 (13.21%) |
2.35 |
0.23 (10.85%) |
0.70 - 3.40 |
33,833,027 |
4,460,000 |
11,236,442 |
|
|
27-02-2024 |
PM |
|
ESPR |
Esperion Therapeutics, Inc. |
296.80 |
-0.50 |
-0.53 |
-0.76 |
Esperion Therapeutics GAAP EPS of -$0.50 misses by $0.02, revenue of $32.25M beats by $3.55M [2/27/2024 6:04 AM] |
2.90 |
0.27 (10.27%) |
2.64 |
0.01 (0.38%) |
0.70 - 6.74 |
9,530,485 |
3,940,000 |
131,951 |
|
|
07-11-2023 |
PM |
|
ESPR |
Esperion Therapeutics, Inc. |
110.20 |
-0.37 |
-0.42 |
-0.81 |
Esperion Therapeutics GAAP EPS of -$0.37 beats by $0.06, revenue of $34M beats by $3.85M [11/7/2023 6:03 AM] |
1.02 |
0.06 (6.69%) |
1.06 |
0.10 (10.85%) |
0.70 - 8.87 |
2,523,150 |
2,840,000 |
243,030 |
|
|
01-08-2023 |
PM |
|
ESPR |
Esperion Therapeutics, Inc. |
144.91 |
-0.46 |
-0.63 |
-1.05 |
Esperion Therapeutics GAAP EPS of -$0.46 beats by $0.15, revenue of $25.79M beats by $1.15M [8/1/2023 6:04 AM] |
1.71 |
0.14 (8.92%) |
1.66 |
0.09 (5.73%) |
1.12 - 8.87 |
8,162,549 |
1,990,000 |
74,633 |
|
|
09-05-2023 |
PM |
7:00 AM ET (May 9) |
ESPR |
Esperion Therapeutics, Inc. |
124.70 |
-0.79 |
-0.65 |
-0.93 |
Esperion Therapeutics GAAP EPS of -$0.79 misses by $0.14, revenue of $24.33M beats by $2.36M [5/9/2023 7:03 AM] |
1.42 |
0.07 (5.19%) |
1.43 |
0.08 (5.93%) |
1.12 - 8.87 |
2,186,887 |
1,940,000 |
17,395 |
|
|
21-02-2023 |
PM |
7:00 AM ET (Feb 21) |
ESPR |
Esperion Therapeutics, Inc. |
414.78 |
-0.76 |
-0.87 |
-1.77 |
Esperion Therapeutics GAAP EPS of -$0.76 beats by $0.09, revenue of $18.8M misses by $1.8M [2/21/2023 7:01 AM] |
5.61 |
-0.31 (-5.32%) |
5.87 |
-0.05 (-0.84%) |
3.81 - 8.87 |
2,928,547 |
1,220,000 |
17,112 |
|
|
01-11-2022 |
PM |
7:00 AM ET (Nov 1) |
ESPR |
Esperion Therapeutics, Inc. |
531.75 |
-0.81 |
-0.93 |
-2.62 |
Esperion Therapeutics GAAP EPS of -$0.81 beats by $0.12, revenue of $19M misses by $0.68M [11/1/2022 7:06 AM] |
8.27 |
0.14 (1.73%) |
8.40 |
0.27 (3.32%) |
3.28 - 10.83 |
1,937,306 |
1,070,000 |
981 |
|
|
02-08-2022 |
PM |
7:00 AM ET (Aug 2) |
ESPR |
Esperion Therapeutics, Inc. |
391.27 |
-1.05 |
-0.95 |
-1.67 |
Esperion Therapeutics GAAP EPS of -$1.05 misses by $0.13, revenue of $18.84M beats by $0.22M [8/2/2022 7:05 AM] |
5.86 |
0.41 (7.52%) |
5.53 |
0.08 (1.47%) |
3.28 - 15.89 |
796,405 |
660,000 |
5,046 |
|
|
03-05-2022 |
PM |
7:00 AM ET (May 3) |
ESPR |
Esperion Therapeutics |
347.00 |
-0.93 |
-0.96 |
0.00 |
Esperion Therapeutics GAAP EPS of -$0.93 beats by $0.11, revenue of $18.83M beats by $3.42M [5/3/2022 7:13 AM] |
6.53 |
0.80 (13.87%) |
5.77 |
0.04 (0.70%) |
3.28 - 26.81 |
2,189,262 |
1,263,553 |
2,263 |
|
|
22-02-2022 |
PM |
7:00 AM ET (Feb 22) |
ESPR |
Esperion Therapeutics, Inc. |
238.12 |
-1.77 |
-2.32 |
-3.89 |
Esperion Therapeutics GAAP EPS of -$1.77 beats by $0.52, revenue of $15.4M beats by $0.92M [2/22/2022 7:02 AM] |
4.34 |
0.51 (13.15%) |
3.95 |
0.11 (2.86%) |
3.28 - 32.00 |
1,967,886 |
1,140,000 |
3,152 |
|
|
02-11-2021 |
PM |
7:00 AM ET (Nov 2) |
ESPR |
Esperion Therapeutics, Inc. |
237.18 |
-2.62 |
-2.86 |
-3.07 |
Esperion Therapeutics EPS beats by $0.22, beats on revenue [11/2/2021 7:16 AM] |
10.31 |
0.20 (1.98%) |
10.31 |
0.0 (0.00%) |
7.73 - 39.49 |
1,283,697 |
1,350,000 |
2,122 |
|
|
03-08-2021 |
PM |
7:00 AM ET (Aug 3) |
ESPR |
Esperion Therapeutics, Inc. |
433.88 |
-1.67 |
-1.83 |
4.32 |
Esperion Therapeutics EPS beats by $0.19, misses on revenue [8/3/2021 7:08 AM] |
14.27 |
-0.72 (-4.84%) |
14.97 |
-0.02 (-0.13%) |
13.74 - 41.48 |
1,285,770 |
740,000 |
2,349 |
|
|
04-05-2021 |
AH |
4:10 PM ET (May 4) |
ESPR |
Esperion Therapeutics, Inc. |
774.57 |
-3.50 |
-2.08 |
-2.84 |
Esperion Therapeutics EPS misses by $0.77, misses on revenue; provides outlook [5/4/2021 4:07 PM] |
20.01 |
-5.58 (-21.81%) |
18.36 |
-7.23 (-28.25%) |
18.01 - 53.73 |
5,132,823 |
470,000 |
753,134 |
|
|
23-02-2021 |
AH |
4:00 PM ET (Feb 23) |
ESPR |
Esperion Therapeutics, Inc. |
764.65 |
-3.89 |
-3.76 |
-2.26 |
Esperion Therapeutics EPS misses by $0.16, misses on revenue [2/23/2021 4:10 PM] |
28.62 |
0.74 (2.65%) |
29.26 |
1.38 (4.95%) |
23.90 - 67.59 |
673,874 |
835,876 |
1,148 |
|
|
02-11-2020 |
AH |
4:00 PM ET (Nov 2) |
ESPR |
Esperion Therapeutics, Inc. |
872.61 |
-3.07 |
-3.52 |
-2.52 |
Esperion Therapeutics EPS beats by $0.49, misses on revenue [11/2/2020 4:20 PM] |
24.23 |
-4.76 (-16.41%) |
25.67 |
-3.32 (-11.45%) |
23.90 - 76.98 |
4,216,296 |
528,950 |
88,856 |
|
|
10-08-2020 |
AH |
4:05 PM ET (Aug 10) |
ESPR |
Esperion Therapeutics, Inc. |
1,070 |
4.32 |
2.13 |
-2.01 |
Esperion Therapeutics EPS beats by $2.09, beats on revenue [8/10/2020 4:13 PM] |
34.67 |
-2.33 (-6.30%) |
36.10 |
-0.90 (-2.43%) |
24.82 - 76.98 |
1,207,000 |
704,273 |
14,578 |
|
|
06-05-2020 |
AH |
|
ESPR |
Esperion Therapeutics, Inc. |
1,080 |
-2.84 |
-3.14 |
3.07 |
|
0.0 |
0.0 (0.00%) |
0.0 |
0.0 (0.00%) |
0.0 - 0.0 |
0 |
0 |
0 |
|
|